Figueroa-Medrano LP, Ávila-Figueroa C

Language: Spanish
References: 39
Page: 149-155
PDF size: 87.87 Kb.

ABSTRACT

Neurological development is a fundamental part of a child’s healthy growth, however, there are factors that can stop his development or that can cause deterioration, amongst them infectious and socio-cultural factors. In some cases, children that are born from a mother infected with the Human Immunodeficiency Virus (HIV) acquire the infection and in others they can escape it. Apart from the condition of their infection status, there is a subgroup of children that additionally have in uterus pharmacological exposure to antiretrovirals, used by their mothers during gestation. It is well known that children infected with HIV have a vast variety of cognitive and motor disturbances, and that as the immunodeficiency progresses, they have a risk of opportunistic infections at cerebral level. It has been demonstrated that even children without infection, but born from infected mothers are not exempt from presenting cognitive and motor disturbances. The different neurological problems that children born from HIV+ mothers present are not only explained by the child’s or mother’s infection, but by the presence of adverse factors, socio cultural ones, that can affect cerebral development on different levels. Due to this situation it is important to recognize neurological alterations as early as possible with the aim of providing a timely management and even to prevent them.

REFERENCES

1. Needdlman R. Crecimiento y desarrollo. En: Behrman RE, Kliegman RM, Arvin AM. Tratado de pediatría de Nelson. Volumen I, 15ª ed., México: Mac Graw Hill-Interamericana; 1997.

2. Chadwick EG, Yoger R. Pediatric AIDS. Pediat Clin of North Am 1995; 42: 969-92.

3. Nielsen K. Treating children for HIV and AIDS GMHC Treat Issues 1997; 11: 36-8. PMID: 11364655 [PubMed - indexed for MEDLINE].

4. 4 . Msellati P, Lepage P, Hitimana D, Van Goethem C, Van de Perre P, Dabis Francois. Neurodevelopmental testing of children born to human immunodeficiency virus type I seropositive and seronegative mothers: A prospective cohort study in Kigali, Rwanda. Pediatrics 1993; 92: 843-8.

5. Aylward EH, Butz AM, Hutton N, Joyner ML, Vogelhut JW. Cognitive and motor development in infants at risk for human immunodeficiency virus. Am J Disease of Child 1992; 146: 218-22.

6. Chase C, Ware J, Hittelman J, Blasini I, Smith R, Llorente A, et al. Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Group. Pediatrics 2000; 106: E25.

7. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80.

8. Andiman WA. Medical management of the pregnant woman infected with HIV-1 and her child. Sem Perinatol 1998; 22: 72-86.

9. Mandelbrot L, Le Chenadec J, Berrebi A, Bongain A, Benifla JL, Delfraissy JF et al. Perinatal HIV-1 transmission-interaction between zidovudine prophylaxis and mode of delivery in the French perinatal cohort. J Am Med Assoc 1998; 280: 55-60.

10. Thorne C, Newell ML. Epidemiology of HIV infection in the newborn. Ear Hum Develop 2000; 58: 1-16.

11. Kind C, Rudin C, Siegrist C-A, Wyler CA, Biedermann K, Lauper U, et al. Prevention of vertical HIV transmission: additive protective effect of elective cesarean section and zidovudine prophylaxis. AIDS 1998; 12: 205-10.

12. Miller R. Anti-HIV therapy during pregnancy: Risk-benefit ratio. Teratology 2000; 62: 288-90.

13. Minkoff H, Augernbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol 1997; 176: 478-89.

14. Brinkman K, Hadewych JM, Burger DM, Smetink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44.

15. Centers for Disease Control and Prevention: Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 in the United States. MMWR 1998, 47 (R-R-2): 1-30.

16. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9.

17. Public Health Service Task Force Recommendations for the use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 in the United States, August 30, 2002. Disponible en: http//www.hivatis.org.

18. Guidelines for use of antiretroviral agents in pediatric HIV infection. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. United States Agosto 8, 2001. Disponible en: http//www.hivatis.org.

19. Pearson DA, McGrath NM, Nozyce M, Nichols SL, Raskino C, Brouwers P, et al. Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatrics 2000; 106(6). Disponible en: http//www.pediatrics.org/cgi/content/full/106/6/e76

20. Drotar D, Olness K, Wiznitzer M, Guay L, Marum L, Svilart G, et al. Neurodevelopmental outcomes of Ugandan infants with human immunodeficiency virus type 1 infection. Pediatrics 2000; 100(1). Disponible en: http//www.pediatrics.org/cgi/content/full/100/1/e5.

21. Nozyce M, Hittelman, Muenz L, Durako S, Fischer ML, Willoughby. Effect of perinatally acquired human immunodeficiency virus infection on neurodevelopment in children during the first two years of life. Pediatrics 1994; 94: 891-3.

22. Coplan J, Contello KA, Cunningham CK, Weiner LB, Dye T, Roberge L, et al. Early language development in children exposed to or infected with human immunodeficiency virus. Pediatrics 1998; 102(1). Disponible en: http//www.pediatrics.org/cgi/content/full/102/1/e8.

23. Raskino C, Pearson D, Baker CJ, Lifschitz MH, O’Donell K, Mintz M, et al. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus- infected children receiving different nucleoside antiretroviral regimens. Pediatrics 1999; 104(3). Disponible en: http//www.pediatrics.org/cgi/content/full/104/3/e32.

24. Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O’Donnell K, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 1999; 281: 151-7.

25. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M. Safety of the maternal-infant zidovudine regimen utilized in the pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998; 12: 1805-13.

26. Mofenson LM, Fowler MG. Interruption of materno-fetal transmission. AIDS 1999; 13(Suppl. A): S205-14.

27. Taylor G, Lyall H, Mercey D, Smith R, et al. British HIV Association Guidelines for Prescribing Antirretroviral Therapy in Pregnancy (1998). Sexually Transmitted Infections (London) 1999; 75: 90-8.

28. Reiff-Eldridge R, Heffner C, Ephross A, Tennis P, White A, Andrews E. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical commitment. Am J Obstet Gynecol 2000; 182(1 Pt 1): 159-63.

29. Shetty A, Maldonado Y. Preventing mother to child transmission of HIV-1: an international perspective. NeoReviews 2001; 2: E75-e82.

30. Mofenson. Perinatal exposure to zidovudine-benefits and risks. N Engl J Med 2000; 343: 803-5.

31. Cooper ER, Charurat M, Burns D, Blattner W, Hoff R. Trends in antirretroviral therapy and mother-infant transmission of HIV 1999. J Acquired Immuno Deficiency Syndromes 2000; 24: 45-7.

32. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12: F241-7.

33. Venerosi A, Valanzano A, Alleva E. Effects of prenatal AZT+3TC treatment on open field behavior and responsiveness to scopolamine in adult mice. Pharmacol Biochem Behav 2000; 67: 511-17.

34. Calamandrei G, Venerosi A, Branchi I, Valanzano A, Puopolo M, Alleva E. Neurobehavioral effects of prenatal lamivudine (3TC) exposure in preweaning mice. Neurotoxicol Teratol 1999; 21: 365-73.

35. Calamandrei G, Venerosi A, Branchi I, Valanzano A, Puopolo M, Alleva E. Prenatal exposure to anti-HIV drugs, long-term neurobehavioral effects of lamivudine (3TC) in CD-1 mice. Neurotoxicol Teratol 2000; 22: 369-79.

36. Calamandrei G, Venerosi A, Branchi I, Chiarotti F, Verdina A, Bucci F, et al. Effects of prenatal AZT on mouse neurobehavioral development and passive avoidance learning. Neurotoxicol Teratol 1999; 21: 29-40.

37. Venerosi A, Valanzano A, Alleva E, Calamandrei G. Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice. Teratology 2001; 63: 23-37.

38. Lindergren M, Rhodes P, Gordon L, Fleming P. Drug safety during pregnancy and in infants. Lack of mortality related to mitocondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann NY Acad Sci 2000; 918: 222-35.

39. Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann N Y Acad Sci 2000; 918: 212-21.